NCT01406574View on ClinicalTrials.gov

Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

OPB-31121

Oral administration, 400 mg/day or 600 mg once daily after breakfast during the treatment period (1 month)

DRUG

OPB-31121 phase2

Oral administration, recommended dose from Phase1 once daily after breakfast during the treatment period (6 months)

Trial Locations (2)

Unknown

Chiba

Tokyo

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

NCT01406574 - Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter